サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1787002

個別化医療市場、規模、シェア、動向、産業分析レポート：製品別、最終用途別、地域別-2025～2034年市場予測

Personalized Medicine Market Size, Share, Trend, Industry Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Others), By End Use, By Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 129 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.45円
個別化医療市場、規模、シェア、動向、産業分析レポート：製品別、最終用途別、地域別-2025～2034年市場予測
出版日: 2025年07月01日
発行: Polaris Market Research
ページ情報: 英文 129 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Researchの最新調査によると、個別化医療市場規模は2034年までに1兆3,002億米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

個別化医療市場は、遺伝子、環境、ライフスタイルのデータを臨床決定の指針として利用し、各患者の特性に合わせた治療を行うことに焦点を当てています。ゲノム解読、分子診断、バイオインフォマティクスの急速な進歩は、予測、予防、的確な標的介入を可能にし、従来型ヘルスケアを一変させました。バイオマーカーによる治療法の臨床への統合は、腫瘍学、神経学、循環器学にわたる治療プロトコルを再構築しています。価値観による医療が重視されるようになったことで、副作用を最小限に抑え、治療成績を向上させる標的治療への需要が加速しています。直接消費者に提供される遺伝子検査の増加と患者の意識の高まりにより、カスタマイズ型ウェルネスと予防戦略へのアクセスが拡大しています。

製薬会社は、臨床検査の成果と規制当局の承認効率を最適化するため、バイオマーカー探索とコンパニオン診断に投資しています。市場動向には、マルチオミクスプロファイリング、AIを活用した意思決定ツール、個別化デジタル治療へのシフトが含まれます。個別化ケアモデルをプライマリケアの枠組みに統合し、電子カルテを活用して臨床-ゲノムデータの統合をサポートすることにビジネス機会があります。精密医療治療の保険適用に対する支払者の関心の高まりは、新たな商業的経路を生み出しています。

希少疾患ゲノミクスと層別化医療イニシアティブに焦点を当てた官民パートナーシップは、イノベーションパイプラインを強化しています。診断学、治療学、データサイエンスの融合が個別化医療の可能性を最大限に引き出し、現代医療の中心的柱となっています。個別化された栄養学や微生物学に焦点を当てた介入が受け入れられつつあることも、全人的な健康管理への幅広いシフトを示唆しています。個別化医療市場は、利害関係者が臨床的有用性、技術的能力、規制当局の支援を調整し、個別化ヘルスケアソリューションを推進することで、今後数年間で急速に進化すると予想されます。

個別化医療市場レポートハイライト

製品別では、個別化栄養と健康セグメントが2024年の売上シェアで～33%を占めます。予防医療や生活習慣病に対する消費者の意識の高まりにより、オーダーメイドの栄養ウェルネスソリューションに対する需要が高まっています。

最終用途別では、病院セグメントが2024年に最大のシェアを占めました。先進的インフラと分子検査プラットフォームへの幅広いアクセスにより、病院は精密医療を実施するための重要な拠点となっています。

北米は、ゲノム技術、高度診断、精密治療が臨床現場で多く採用されているため、2024年の売上シェアの40%を占めています。

アジア太平洋の個別化医療市場は、2025～2034年にかけてCAGR 12.2%を記録すると予想されています。人口密度の高い国々における個別化医療に対する需要の急増、医療支出の増加、ゲノムサービスへのアクセスの拡大が市場拡大の原動力となっているためです。

世界の主要企業には、Abbott、ASURAGEN, INC.、Biogen、Celera Diagnostics LLC.、Dako A/S、Danaher Corporation（Cepheid, Inc.）、Decode Genetics, Inc.、Exact Sciences Corporation、Exagen Inc.、GE Healthcare、Genelex、Illumina, Inc.、Precision Biologics、QIAGENなどがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の個別化医療市場洞察

  • 市場スナップショット
  • 個別化医療市場力学
    • 促進要因と機会
      • 慢性疾患と希少疾患の有病率の増加
      • 製薬企業とバイオテクノロジー企業による研究開発投資の増加
    • 抑制要因と課題
      • 開発と診断コストが高め
  • PESTEL分析
  • 個別化医療市場の用途動向
  • バリューチェーン分析

第5章 世界の個別化医療市場：製品別

  • 主要調査結果
  • イントロダクション
  • 個別化医療診断
  • 個別化医療治療
  • 個別化医療
  • 個別化栄養と健康

第6章 世界の個別化医療市場：最終用途別

  • 主要調査結果
  • イントロダクション
  • 病院
  • 診断センター
  • 研究・学術機関
  • その他

第7章 世界の個別化医療市場：地域

  • 主要調査結果
  • イントロダクション
    • 個別化医療市場評価：地域、2020～2034年
  • 北米
    • 北米：製品別、2020～2034年
    • 北米：最終用途別、2020～2034年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州：製品別、2020～2034年
    • 欧州：最終用途別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他の欧州
  • アジア太平洋
    • アジア太平洋：製品別、2020～2034年
    • アジア太平洋：最終用途別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他のアジア太平洋
  • 中東・アフリカ
    • 中東・アフリカ：製品別、2020～2034年
    • 中東・アフリカ：最終用途別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：製品別、2020～2034年
    • ラテンアメリカ：最終用途別、2020～2034年
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Abbott
  • ASURAGEN, INC.
  • Biogen
  • Celera Diagnostics LLC.
  • Dako A/S
  • Danaher Corporation（Cepheid, Inc.）
  • Decode Genetics, Inc.
  • Exact Sciences Corporation
  • Exagen Inc.
  • GE Healthcare
  • Genelex
  • Illumina, Inc.
  • Precision Biologics
  • QIAGEN
図表

List of Tables:

  • Table 1 Global Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 2 Global Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 3 North America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 4 North America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 5 U.S.: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 6 U.S.: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 7 Canada: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 8 Canada: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 9 Mexico: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 10 Mexico: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 11 Europe: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 12 Europe: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 13 UK: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 14 UK: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 15 France: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 16 France: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 17 Germany: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 18 Germany: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 19 Italy: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 20 Italy: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 21 Spain: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 22 Spain: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 23 Netherlands: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 24 Netherlands: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 25 Russia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 26 Russia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 27 Rest of Europe: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 28 Rest of Europe: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 29 Asia Pacific: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 30 Asia Pacific: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 31 China: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 32 China: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 33 India: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 34 India: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 35 Malaysia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 36 Malaysia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 37 Japan: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 38 Japan: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 39 Indonesia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 40 Indonesia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 41 South Korea: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 42 South Korea: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 43 Australia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 44 Australia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 45 Rest of Asia Pacific: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 46 Rest of Asia Pacific: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 47 Middle East & Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 48 Middle East & Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 49 Saudi Arabia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 50 Saudi Arabia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 51 UAE: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 52 UAE: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 53 Israel: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 54 Israel: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 55 South Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 56 South Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 57 Rest of Middle East & Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 58 Rest of Middle East & Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 59 Latin America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 60 Latin America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 61 Brazil: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 62 Brazil: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 63 Argentina: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 64 Argentina: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Personalized Medicine Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Product
  • Figure 7. Global Personalized Medicine Market, by Product, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End Use
  • Figure 9. Global Personalized Medicine Market, by End Use, 2024 & 2034 (USD Billion)
目次
Product Code: PM5986

The personalized medicine market size is expected to reach USD 1,300.20 billion by 2034, according to a new study by Polaris Market Research. The report "Personalized Medicine Market Size, Share, Trend, Industry Analysis Report By Product (Personalized Medicine Diagnostics, Personalized Medicine Therapeutics, Others), By End Use, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The personalized medicine market focuses on tailoring medical treatment to the individual characteristics of each patient, using genetic, environmental, and lifestyle data to guide clinical decisions. Rapid advances in genomic sequencing, molecular diagnostics, and bioinformatics have transformed traditional healthcare by enabling predictive, preventive, and precisely targeted interventions. The integration of biomarker-based therapies into clinical practice is reshaping treatment protocols across oncology, neurology, and cardiology. Increasing emphasis on value-based care is accelerating demand for targeted drugs that minimize adverse effects and improve therapeutic outcomes. The growth in direct-to-consumer genetic testing and increasing patient awareness is expanding access to customized wellness and preventive strategies.

Pharmaceutical companies are investing in biomarker discovery and companion diagnostics to optimize clinical trial outcomes and regulatory approval efficiency. Market trends include a shift toward multi-omics profiling, AI-powered decision-making tools, and personalized digital therapeutics. Opportunities lie in integrating personalized care models into primary care frameworks and leveraging electronic health records to support clinical-genomic data convergence. Increasing interest from payers in covering precision medicine therapies is creating new commercial pathways.

Public-private partnerships focused on rare disease genomics and stratified medicine initiatives are enhancing innovation pipelines. The convergence of diagnostics, therapeutics, and data science is unlocking the full potential of personalized care, making it a central pillar of modern medicine. Growing acceptance of personalized nutrition and microbiome-focused interventions also signals a broader shift toward holistic health management. The personalized medicine market is expected to evolve rapidly in the coming years as stakeholders align clinical utility, technological capabilities, and regulatory support to advance individualized healthcare solutions.

Personalized Medicine Market Report Highlights

By product, the personalized nutrition & wellness segment accounted for ~33% of the revenue share in 2024. Growing consumer awareness about preventive healthcare and lifestyle-related diseases has increased the demand for tailored nutrition and wellness solutions.

Based on end use, the hospitals segment accounted for the largest share in 2024. Advanced infrastructure and broader access to molecular testing platforms make hospitals key centers for implementing precision medicine.

North America accounted for ~40% of the revenue share in 2024 due to high adoption of genomic technologies, advanced diagnostics, and precision therapeutics across clinical settings.

The personalized medicine market in Asia Pacific is expected to register a CAGR of 12.2% from 2025 to 2034, as surging demand for tailored healthcare in densely populated countries, rising healthcare spending, and growing access to genomic services are driving expansion.

A few global key players include Abbott; ASURAGEN, INC.; Biogen; Celera Diagnostics LLC.; Dako A/S; Danaher Corporation (Cepheid, Inc.); Decode Genetics, Inc.; Exact Sciences Corporation; Exagen Inc.; GE Healthcare; Genelex; Illumina, Inc.; Precision Biologics; and QIAGEN.

Polaris Market Research has segmented the personalized medicine market report on the basis of product, end use, and region:

By Product Outlook (Revenue, USD Billion, 2020-2034)

Personalized Medicine Diagnostics

Genetic Testing

Direct-To-Consumer (DTC) Diagnostics

Others

Personalized Medicine Therapeutics

Pharmaceutical

Genomic Medicine

Medical Devices

Personalized Medical Care

Personalized Nutrition & Wellness

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Hospitals

Diagnostic Centers

Research & Academic Institutes

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Personalized Medicine Market Insights

  • 4.1. Personalized Medicine Market - Market Snapshot
  • 4.2. Personalized Medicine Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Prevalence of Chronic and Rare Diseases
      • 4.2.1.2. Increased Investment in R&D by Pharma and Biotech Firms
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High development and diagnostic costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Personalized Medicine Market Application Trends
  • 4.6. Value Chain Analysis

5. Global Personalized Medicine Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
  • 5.3. Personalized Medicine Diagnostics
    • 5.3.1. Global Personalized Medicine Market, by Personalized Medicine Diagnostics, by Region, 2020-2034 (USD Billion)
    • 5.3.2. Genetic Testing
      • 5.3.2.1. Global Personalized Medicine Market, by Genetic Testing, by Region, 2020-2034 (USD Billion)
    • 5.3.3. Direct-To-Consumer (DTC) Diagnostics
      • 5.3.3.1. Global Personalized Medicine Market, by Direct-To-Consumer (DTC) Diagnostics, by Region, 2020-2034 (USD Billion)
    • 5.3.4. Others
      • 5.3.4.1. Global Personalized Medicine Market, by Others, by Region, 2020-2034 (USD Billion)
  • 5.4. Personalized Medicine Therapeutics
    • 5.4.1. Global Personalized Medicine Market, by Personalized Medicine Therapeutics, by Region, 2020-2034 (USD Billion)
    • 5.4.2. Pharmaceutical
      • 5.4.2.1. Global Personalized Medicine Market, by Pharmaceutical, by Region, 2020-2034 (USD Billion)
    • 5.4.3. Genomic Medicine
      • 5.4.3.1. Global Personalized Medicine Market, by Genomic Medicine, by Region, 2020-2034 (USD Billion)
    • 5.4.4. Medical Devices
      • 5.4.4.1. Global Personalized Medicine Market, by Medical Devices, by Region, 2020-2034 (USD Billion)
  • 5.5. Personalized Medical Care
    • 5.5.1. Global Personalized Medicine Market, by Personalized Medical Care, by Region, 2020-2034 (USD Billion)
  • 5.6. Personalized Nutrition & Wellness
    • 5.6.1. Global Personalized Medicine Market, by Others, by Personalized Nutrition & Wellness, 2020-2034 (USD Billion)

6. Global Personalized Medicine Market, by End Use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • 6.3. Hospitals
    • 6.3.1. Global Personalized Medicine Market, by Hospitals, by Region, 2020-2034 (USD Billion)
  • 6.4. Diagnostic Centers
    • 6.4.1. Global Personalized Medicine Market, by Diagnostic Centers, by Region, 2020-2034 (USD Billion)
  • 6.5. Research & Academic Institutes
    • 6.5.1. Global Personalized Medicine Market, by Research & Academic Institutes, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Personalized Medicine Market, by Othersr, by Region, 2020-2034 (USD Billion)

7. Global Personalized Medicine Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Personalized Medicine Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Personalized Medicine Market - North America
    • 7.3.1. North America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
    • 7.3.2. North America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.3.3. Personalized Medicine Market - U.S.
      • 7.3.3.1. U.S.: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.3.4. Personalized Medicine Market - Canada
      • 7.3.4.1. Canada: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.3.5. Personalized Medicine Market - Mexico
      • 7.3.5.1. Mexico: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.3.5.2. Mexico: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • 7.4. Personalized Medicine Market - Europe
    • 7.4.1. Europe: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.3. Personalized Medicine Market - UK
      • 7.4.3.1. UK: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.4. Personalized Medicine Market - France
      • 7.4.4.1. France: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.5. Personalized Medicine Market - Germany
      • 7.4.5.1. Germany: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.6. Personalized Medicine Market - Italy
      • 7.4.6.1. Italy: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.7. Personalized Medicine Market - Spain
      • 7.4.7.1. Spain: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.8. Personalized Medicine Market - Netherlands
      • 7.4.8.1. Netherlands: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.9. Personalized Medicine Market - Russia
      • 7.4.9.1. Russia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.4.10. Personalized Medicine Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • 7.5. Personalized Medicine Market - Asia Pacific
    • 7.5.1. Asia Pacific: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.3. Personalized Medicine Market - China
      • 7.5.3.1. China: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.4. Personalized Medicine Market - India
      • 7.5.4.1. India: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.5. Personalized Medicine Market - Malaysia
      • 7.5.5.1. Malaysia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.6. Personalized Medicine Market - Japan
      • 7.5.6.1. Japan: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.7. Personalized Medicine Market - Indonesia
      • 7.5.7.1. Indonesia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.8. Personalized Medicine Market - South Korea
      • 7.5.8.1. South Korea: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.9. Personalized Medicine Market - Australia
      • 7.5.9.1. Australia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.5.10. Personalized Medicine Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • 7.6. Personalized Medicine Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.3. Personalized Medicine Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.4. Personalized Medicine Market - UAE
      • 7.6.4.1. UAE: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.5. Personalized Medicine Market - Israel
      • 7.6.5.1. Israel: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.6. Personalized Medicine Market - South Africa
      • 7.6.6.1. South Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.6.7. Personalized Medicine Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
  • 7.7. Personalized Medicine Market - Latin America
    • 7.7.1. Latin America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.7.3. Personalized Medicine Market - Brazil
      • 7.7.3.1. Brazil: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.7.3.2. Brazil: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.7.4. Personalized Medicine Market - Argentina
      • 7.7.4.1. Argentina: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.7.4.2. Argentina: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)
    • 7.7.5. Personalized Medicine Market - Rest of Latin America
      • 7.7.5.1. Rest of Latin America: Personalized Medicine Market, by Product, 2020-2034 (USD Billion)
      • 7.7.5.2. Rest of Latin America: Personalized Medicine Market, by End Use, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Abbott
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. ASURAGEN, INC.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Biogen
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Celera Diagnostics LLC.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Dako A/S
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Danaher Corporation (Cepheid, Inc.)
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Decode Genetics, Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Exact Sciences Corporation
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Exagen Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. GE Healthcare
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Genelex
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Illumina, Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Precision Biologics
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. QIAGEN
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development